SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

26 May 2026 Evaluate
The sales declined to Rs. 280.31 millions for the March 2026 quarter as compared to Rs. 305.17 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2026 is Rs. -297.71 millions as compared to Net Profit of Rs. 12.31 millions of corresponding quarter ended March 2025Operating profit Margin for the quarter ended March 2026 slipped to -39.72% as compared to 41.20% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 280.31 305.17 -8.15 1209.05 1346.97 -10.24 1209.05 1346.97 -10.24
Other Income 5.10 8.22 -37.96 39.74 27.60 43.99 39.74 27.60 43.99
PBIDT -39.72 41.20 -196.41 15.66 201.72 -92.24 15.66 201.72 -92.24
Interest 8.73 5.20 67.88 33.27 23.05 44.34 33.27 23.05 44.34
PBDT -278.59 36.00 -873.86 -247.75 178.67 -238.66 -247.75 178.67 -238.66
Depreciation 20.44 14.17 44.25 84.60 67.66 25.04 84.60 67.66 25.04
PBT -299.03 21.83 -1469.81 -332.35 111.01 -399.39 -332.35 111.01 -399.39
TAX -1.32 9.52 -113.87 -9.47 31.83 -129.75 -9.47 31.83 -129.75
Deferred Tax -4.70 2.76 -270.29 -17.75 4.57 -488.40 -17.75 4.57 -488.40
PAT -297.71 12.31 -2518.44 -322.88 79.18 -507.78 -322.88 79.18 -507.78
Equity 356.90 356.90 0.00 356.90 356.90 0.00 356.90 356.90 0.00
PBIDTM(%) -14.17 13.50 -204.96 1.30 14.98 -91.35 1.30 14.98 -91.35

Lyka Labs Share Price

62.00 1.73 (2.87%)
05-Jun-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.10
Dr. Reddys Lab 1272.70
Cipla 1392.10
Zydus Lifesciences 1089.90
Lupin 2281.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×